Last reviewed · How we verify
Recommendation and Counseling for Alcohol Pharmacotherapy
Recommendation and Counseling for Alcohol Pharmacotherapy, developed by the University of Alabama at Birmingham, is a marketed intervention aimed at addressing alcohol use disorders. The key composition patent is set to expire in 2028, providing a period of exclusive market protection. The primary risk is the lack of a clear revenue stream or key trial results to support its market position.
At a glance
| Generic name | Recommendation and Counseling for Alcohol Pharmacotherapy |
|---|---|
| Also known as | Recommendation for APT |
| Sponsor | University of Alabama at Birmingham |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- ItaliaN Study With Tailored Multidomain Interventions to Prevent Functional and Cognitive Decline in Community-dwelling Older Adults (NA)
- Alcohol Research Consortium in HIV-Intervention Research Arm (PHASE4)
- Blended Collaborative Care for Heart Failure and Co-Morbid Depression (PHASE2, PHASE3)
- Multimodal Prehabilitation in Thoracic Surgery (NA)
- Hepatitis C Translating Initiatives for Depression Into Effective Solutions (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: